Methods of treating pain using antagonists of IL-31, IL-31RA...

Details Methods of treating pain using antagonists of IL-31, IL-31RA... Methods of treating pain using antagonists of IL-31, IL-31RA...

2011-05-17

2011-05-17

Saoud, Christine J (Department: 1647)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S133100, C424S135100, C424S141100, C424S143100, C514S002600, C514S012200, C530S350000

Reexamination Certificate

active

07943132

ABSTRACT:
Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

REFERENCES:
patent: 5116964 (1992-05-01), Capon et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5891997 (1999-04-01), Mosley et al.
patent: 5925735 (1999-07-01), Baumgartner et al.
patent: 6043344 (2000-03-01), Jacobs et al.
patent: 7064186 (2006-06-01), Sprecher et al.
patent: 7303896 (2007-12-01), Ghilardi et al.
patent: 7425325 (2008-09-01), Sprecher et al.
patent: 7427494 (2008-09-01), Sprecher et al.
patent: 7459293 (2008-12-01), Sprecher et al.
patent: 7494804 (2009-02-01), Sprecher et al.
patent: 7495080 (2009-02-01), Sprecher et al.
patent: 7507795 (2009-03-01), Sprecher et al.
patent: 7514077 (2009-04-01), Yao et al.
patent: 7521537 (2009-04-01), Sprecher et al.
patent: 7531636 (2009-05-01), Sprecher et al.
patent: 7531637 (2009-05-01), Siadak et al.
patent: 7638126 (2009-12-01), Yao et al.
patent: 7740834 (2010-06-01), Sprecher et al.
patent: 2003/0096339 (2003-05-01), Sprecher et al.
patent: 2004/0142422 (2004-07-01), Sprecher et al.
patent: 2004/0152161 (2004-08-01), Cosman et al.
patent: 2005/0214801 (2005-09-01), Sprecher et al.
patent: 2006/0182743 (2006-08-01), Bilsborough
patent: 2006/0188499 (2006-08-01), Leung et al.
patent: 2006/0188500 (2006-08-01), Leung et al.
patent: 2006/0228329 (2006-10-01), Brady et al.
patent: 2007/0048222 (2007-03-01), Sprecher et al.
patent: 2007/0048223 (2007-03-01), Sprecher et al.
patent: 2007/0048303 (2007-03-01), Sprecher et al.
patent: 2007/0048307 (2007-03-01), Sprecher et al.
patent: 2007/0048308 (2007-03-01), Sprecher et al.
patent: 2007/0048831 (2007-03-01), Sprecher et al.
patent: 2007/0048832 (2007-03-01), Sprecher et al.
patent: 2007/0048833 (2007-03-01), Sprecher et al.
patent: 2007/0048834 (2007-03-01), Sprecher et al.
patent: 2007/0048835 (2007-03-01), Sprecher et al.
patent: 2007/0049530 (2007-03-01), Sprecher et al.
patent: 2007/0105777 (2007-05-01), Sprecher et al.
patent: 2007/0140963 (2007-06-01), Sprecher et al.
patent: 2007/0140964 (2007-06-01), Sprecher et al.
patent: 2007/0141051 (2007-06-01), Sprecher et al.
patent: 2008/0026402 (2008-01-01), Cosman et al.
patent: 2008/0260686 (2008-10-01), Bilsborough et al.
patent: 2009/0092999 (2009-04-01), Bilsborough et al.
patent: 2009/0149635 (2009-06-01), Sprecher et al.
patent: 2009/0208494 (2009-08-01), Bondensgaard et al.
patent: 2009/0220417 (2009-09-01), Siadak et al.
patent: 2009/0252730 (2009-10-01), Bilsborough
patent: 2009/0252732 (2009-10-01), Siadak et al.
patent: 2009/0274694 (2009-11-01), Sprecher et al.
patent: 2009/0274700 (2009-11-01), Sprecher et al.
patent: 2009/0280121 (2009-11-01), Bilsborough et al.
patent: 2010/0008909 (2010-01-01), Siadak et al.
patent: 2010/0055101 (2010-03-01), Sprecher et al.
patent: 2010/0266499 (2010-10-01), Sprecher et al.
patent: 2010/0266597 (2010-10-01), Sprecher et al.
patent: 2010/0266600 (2010-10-01), Bilsborough et al.
patent: 1188830 (2002-03-01), None
patent: 10-501131 (1998-02-01), None
patent: 00/75314 (2000-12-01), None
patent: 01/93983 (2001-12-01), None
patent: 02/00690 (2002-01-01), None
patent: 02/00721 (2002-01-01), None
patent: 02/08288 (2002-01-01), None
patent: 02/29060 (2002-04-01), None
patent: 02/77230 (2002-10-01), None
patent: 03/072740 (2003-09-01), None
patent: 2004/003140 (2004-01-01), None
patent: 06/088955 (2006-08-01), None
patent: 06/088956 (2006-08-01), None
patent: 07/143231 (2007-12-01), None
patent: 2008/028192 (2008-03-01), None
patent: 08/086505 (2008-07-01), None
patent: 09/071696 (2009-06-01), None
Riken, 1999, (GenBank Acc. No. AV040649).
Riken, 1999, (GenBank Acc. No. AV044404).
Riken, 1999, (GenBank Acc. No. AV268991).
Riken, 1999, (GenBank Acc. No. AV280874).
National Cancer Institute, 1997, (GenBank Acc. No. BF152807).
Riken, 2001, (GenBank Acc. No. BB610257).
Riken, Accession No. AK005939, 1999.
Riken, Accession No. AK005939, 2001.
National Institutes of Health, 1999, (GenBank Acc. No. CA464033).
Riken, 2002, (GenBank Acc. No. BY706076).
Washington University School of Medicine, 2002, (GenBank Acc. No. CF105870).
RZPD Deutsches Ressourcenzentrum fuer Genomforschung GmbH, 2003, (GenBank Acc. No. BX639332).
Whitehead Institute for Biomedical Research, Mouse Public Genomic Sequence TDB 3482986, Jan. 11, 2001.
Washington University Genome Sequencing Center, Mouse Public Genomic Sequence TDB 16727183, Feb. 24, 2001.
Whitehead Institute for Biomedical Research, Mouse Public Genomic Sequence TDB 10456006, Mar. 14, 2001.
Washington University Genome Sequencing Center, Mouse Public Genomic Sequence TDB 8480322, Jan. 13, 2001.
Whitehead Institute for Biomedical Research, Mouse Public Genomic Sequence TDB 49775248, Oct. 5, 2001.
Whitehead Institute for Biomedical Research, Mouse Public Genomic Sequence TDB 10005090, Mar. 10, 2001.
Whitehead Institute for Biomedical Research, Mouse Public Genomic Sequence TDB 20965871, Mar. 16, 2001.
Whitehead Institute for Biomedical Research, Mouse Public Genomic Sequence TDB 44835892, Sep. 20, 2001.
Washington University Genome Sequencing Center, Mouse Public Genomic Sequence TDB 50734527, Oct. 6, 2001.
Sanger Center, Mouse Public Genomic Sequence TDB 40505897, Aug. 31, 2001.
Sanger Center, Mouse Public Genomic Sequence TDB 1021719, Jan. 4, 2001.
Washington University Genome Sequencing Center, Mouse Public Genomic Sequence TDB 22973884, Apr. 16. 2001.
Abstract from the American Society of Human Genetics Meeting, Nov. 7, 2003 on Gene Structure and Function.
EMBL Accession No. AC048338, Apr. 2000.
EMBL Accession No. AA381907, Apr. 1997.
Dillon et al., “Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice,” Nature Immunology 5(7):752-760, Jul. 2004.
Bilsborough et al., “IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T-cells in patients with atopic dermatitis”, Journal of Allergy and Clinical Immunology, Mosby—Yearly Book, Inc., US 117(2): 418-425, Feb. 7, 2006.
Sonkoly et al., “IL-31: A new link between t-cells and pruritus in atopic skin inflammation”, Journal of Allergy and Clinical Immunology, Mosby—Yearly Book, Inc., US 117(2): 411-417, Feb. 2006.
Takaoka A. et al., “Involvement of IL-31 on scratching behavior in NC/Nga mice with atopic-like dermatitis”, Experimental Dermatology, 15 (3): 161-167, Mar. 2006.
Takaoka A. et al., “Expression of IL-31 gene transcript in NC/Nga mice with atopic dermatitis”, European Journal of Pharmacology, Amsterdam, NL, 516 (2): 180-181, May 31, 2005.
Goding, J.W., Journal of Immunological Methods vol. 39: 285-308, 1980.
Brune et al., Hautarzt 55: 1130-1136, 2004.
Ständer et al., Hautarzt 54: 413-417, 2003.
Claudy, A., Pathologic et Biologie, L'Expansion Scientifique Francaise, Paris, FR 44(10): 888-894, 1996.
Leung, D. et al., “New insights into atopic dermititis”,Journal of Clinical Investigation 113(5): 651-657, Mar. 2004.
Boguniewics, M. et al., “Atopic dermititis”,J Allergy Clin Immunol, 117(2): S475-S480, Feb. 2006.
Castellani, M.L. et al., “Interleukin-31: A new cytokine involved in inflammation of the skin”,International Journal of Immunopathology and Pharmacology, 19(1): 1-4, Jan. 13, 2006.
“Monoclonal Anti-human IL-31 Antibody”, R&D Systems, Inc., Apr. 18, 2006.
Presta et al.,Advanced Drug Delivery Reviews 58(5-6): 640-656, 2006.
Neis et al., “Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis,” Journal ofAllergy and Clinical Immunology, 118(4): 930-937, Oct. 1, 2006.
Conti et al., “Modulation of autoimmunity by the latest interleukins (with special emphasis on IL-32)” Autoimmunity Reviews 6(3): 131-137, 2007.
EMBL Accession No.

Affiliated with

Also associated with

Rating

Methods of treating pain using antagonists of IL-31, IL-31RA... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treating pain using antagonists of IL-31, IL-31RA..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating pain using antagonists of IL-31, IL-31RA... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2691736